Moors & Cabot Inc. raised its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 14.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 26,106 shares of the company’s stock after purchasing an additional 3,266 shares during the period. Eli Lilly and Company accounts for about 1.1% of Moors & Cabot Inc.’s portfolio, making the stock its 12th largest position. Moors & Cabot Inc.’s holdings in Eli Lilly and Company were worth $30,206,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of the business. BlackRock Inc. boosted its stake in shares of Eli Lilly and Company by 1.6% during the second quarter. BlackRock Inc. now owns 67,540,400 shares of the company’s stock valued at $81,009,981,000 after purchasing an additional 1,046,558 shares in the last quarter. State Street Corp increased its holdings in Eli Lilly and Company by 1.7% during the second quarter. State Street Corp now owns 36,215,754 shares of the company’s stock valued at $43,438,262,000 after buying an additional 605,752 shares during the period. Bank of America Corp DE purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $13,522,666,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in Eli Lilly and Company by 1.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 7,209,385 shares of the company’s stock worth $8,647,153,000 after buying an additional 137,364 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in Eli Lilly and Company by 7.9% in the second quarter. Jennison Associates LLC now owns 5,461,416 shares of the company’s stock worth $6,550,587,000 after buying an additional 400,538 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.
Eli Lilly and Company Stock Up 0.0%
NYSE:LLY opened at $1,444.05 on Monday. The company’s 50-day simple moving average is $1,242.25 and its 200-day simple moving average is $1,110.30. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a fifty-two week low of $850.51 and a fifty-two week high of $1,460.00. The stock has a market capitalization of $1.36 trillion, a P/E ratio of 46.87, a P/E/G ratio of 1.73 and a beta of 0.40.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, October 29th. The company reported $7.48 EPS for the quarter, topping the consensus estimate of $5.71 by $1.77. The firm had revenue of $24.40 billion during the quarter, compared to analyst estimates of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. Eli Lilly and Company’s revenue was up 38.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $7.02 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.
Eli Lilly and Company Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s payout ratio is currently 22.46%.
Analyst Ratings Changes
LLY has been the subject of a number of analyst reports. Leerink Partners upped their target price on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a report on Wednesday, October 21st. Scotiabank lifted their price target on Eli Lilly and Company from $1,300.00 to $1,605.00 and gave the company a “sector outperform” rating in a report on Friday, October 30th. Weiss Ratings upgraded Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a report on Friday. UBS Group boosted their price target on Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Finally, Citigroup upped their price objective on Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $1,416.64.
Read Our Latest Stock Report on LLY
Insider Transactions at Eli Lilly and Company
In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of Eli Lilly and Company stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the transaction, the executive vice president directly owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.14% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
See Also
- Five stocks we like better than Eli Lilly and Company
- Fossil Just Turned a Profit—Can Its Comeback Survive the Holidays?
- Beaming Up the Backlog: AeroVironment Lands $405M Laser Deal
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
